Tomas Aleman, MD
Retina Specialist · Philadelphia, PANPI 1104110303
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,120 of the $3,279 with a category attached, or 95.1%. Incyte Corporation accounts for 95.1% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $3,120 and has fallen 98.3% since, to $53 in 2023.
Across 6 payments — averaging $546.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$3K
- Alcon$108
- Spark Therapeutics, Inc.$38
- Amgen$14
Across 46 payments — averaging $4049.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Spark Therapeutics, Inc.$166K
- Biogen$20K
What the payments were for
- Consulting fees$3,12095%
- Food & beverage$1595%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 1 | $3,120 |
| Alcon | 3 | $108 |
| Spark Therapeutics, Inc. | 1 | $38 |
| Amgen | 1 | $14 |
How this compares
$3,279 in reported general payments places this provider in the 65th percentile of 43 retina specialist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bromfenac Sodium | 14 | $1,908 |
| Dorzolamide Hcl | 22 | $348 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Philadelphia
- Joshua GreenePhiladelphia$394K
- Brian VanderbeekPhiladelphia$14K
- Albert MaguirePhiladelphia$9K
- Hugo LinaresPhiladelphia$7K
- Benjamin KimPhiladelphia$5K
- Robert CarrollPhiladelphia$1K
- Drew ScolesPhiladelphia$519
- Juan GrunwaldPhiladelphia$508
- Alexander BruckerPhiladelphia$86
- William FosterPhiladelphia$28
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.